Category

news

Tilgmann Group divests Scandiflex Pac AB

Tilgmann Group has reorganized its operations and divested Scandiflex Pac AB to Schur Flexibles. Scandiflex, founded in 1985, is a designer and manufacturer of packaging solutions, predominantly for the food industry but also within other product areas. The company has its headquarters in Landskrona, Sweden, and its turnover during 2018 amounted to approximately SEK 175 million.

Tilgmann Group, founded almost 150 years ago, is active within the packaging business in the Nordic countries.

Tilgmann was advised by HWF Advokater in the transaction.

Diaprost AB announces exercise of option right under the terms of a Research and Option Agreement

In October 2017 Diaprost AB entered into an exclusive Research and Option Agreement with a world leading pharmaceutical company regarding Diaprost’s antibody h11B6. The antibody which targets prostate cancer, the most common cancer in men, has now advanced to clinical development. Taking this into account, the pharmaceutical company has chosen to exercise its option right pursuant to the Research and Option Agreement acquiring Diaprost’s rights to the antibody h11B6. Diaprost has already received payments of USD 13 million and the option and other commercial milestones may trigger additional payments to Diaprost up to USD 90 million.

Diaprost is a private pharmaceutical research and development company which was founded in 2005. The company is based in Lund. Diaprost’s technology has been pursued by researchers at Lund University with support from private investors. Diaprost is collaborating with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine and oncology.

HWF Advokater has jointly with attorney-at-law Ragnar Lindqvist assisted Diaprost in connection with the Research and Option Agreement entered into with the pharmaceutical company and the exercise of the latter’s option right.

EQL Pharma is preparing a listing on Nasdaq Stockholm

The Board of Directors of EQL Pharma AB (publ) has resolved to evaluate the conditions for listing the company’s share on Nasdaq Stockholm’s main list. The list change is expected to take place during the last quarter of 2020. EQL Pharma’s Board of Directors and management will now initiate the work required to prepare the company for a listing on Nasdaq Stockholm.

EQL Pharma’s share has been listed on Spotlight Stock Market since 2013 and in Spotlight’s new segment Next since October 31, 2019. Companies traded in this segment follow stricter rules regarding, among other things, accounting principles than other companies listed on Spotlight Stock Market. The requirements correspond in several respects to the requirements on Nasdaq Stockholm’s main list.

EQL Pharma has engaged HWF Advokater as legal advisor for the planned list change.

SIGNATUR FASTIGHETER’S REVERSE ACQUISITION OF SIG INVEST FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET COMPLETED

Signatur Fastigheter AB (publ) (previously Deflamo AB (publ)), listed on Nasdaq First North Growth Market, and the owners of SIG Invest AB (publ) entered an agreement during the autumn regarding Signatur Fastigheter’s acquisition of all shares in SIG Invest through an issue in kind. The transaction entailed that Deflamo’s business would be changed to SIG Invest’s business whose business idea is to create long-term growth and to increase value through development of residential properties combined with management. After Nasdaq’s conditional approval was obtained, an extraordinary general meeting held on 22 November 2019 resolved to complete the reverse acquisition. In connection with the transaction, Deflamo changed company name to Signatur Fastigheter AB (publ). First trading day on Nasdaq First North Growth Market for the new shares in Signatur Fastigheter was 17 December 2019.

Signatur Fastigheter was advised by HWF Advokater in the reverse acquisition.

SÄKRA ACQUIRES ASSURANSSELECTOR AB

AssuransSelector Holding AB divests AssuransSelector AB to Säkra. AssuransSelector AB is an insurance advisor specialised in Swedish and international insurance solutions within technology, life science, consulting and industry.

AssuransSelector Holding AB was advised by HWF Advokater in the transaction.

ABSOLENT GROUP ACQUIRES INTERZON AB

Absolent Group AB (publ) has acquired Interzon AB, a privately-owned company headquartered in Täby, Sweden, with a manufacturing subsidiary in Tallinn, Estonia. Interzon, with a 2018 turnover of SEK 32 million, develops and manufactures filtration products for oil mist and odour removal in commercial kitchens. The acquisition gives Absolent Group access to a complementary filtration technology and a strong customer base of global fast-food and hotel chains.

Absolent Group is a global company group which, under the trademarks Absolent, Bristol and Filtermist, manufactures and sells air cleaning equipment for the cleaning of industrial process air within the machine tool business. Absolent Group had during 2018 approximately 240 employees and a turnover of around SEK 640 million. The group has its headquarters in Lidköping, Sweden, and production facilities in Sweden, England and Germany and is active, directly or through distributors, in 50 countries around the globe. Absolent Group AB is listed at Nasdaq First North Stockholm.

Absolent Group was advised by HWF Advokater in the transaction.

RIGHTS ISSUE OF AROUND MSEK 41.2 IN ACUCORT

AcuCort AB (publ) carries out a rights issue of shares of around MSEK 41.2. The funds contributed to the company through the rights issue shall primarily be used for the financing of the imminent commercialisation of AcuCort’s innovative drug candidate ISICORT®.

AcuCort develops and commercializes ISICORT® – a new fast-dissolving film that is placed on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting. The bioequivalence study that forms the basis of the application for market approval in Europe is carried out with positive results, which strengthens the assessment that the time until commercialisation of ISICORT® may be relatively short. The AcuCort share is traded at Spotlight Stock Market in Sweden.

HWF Advokater acts as legal advisor to AcuCort in connection with the rights issue.